Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

That trajectory was then compared with what was seen in patients using lecanemab and donanemab during each drug’s clinical trial. A person with typical mild cognitive decline, such as forgetting ...

Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

Health chiefs were today urged to reconsider approving a breakthrough Alzheimer's drug proven to tackle the devastating disease on the NHS. Lecanemab and donanemab were hailed as 'the beginning ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes, living independently, for longer periods of time. Those medications, while effective, are not ...